Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

September 28, 2022

Primary Completion Date

May 18, 2024

Study Completion Date

May 18, 2024

Conditions
Hyperuricemia
Interventions
DRUG

D-0120

Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.

DRUG

Benzbromarone

Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.

Trial Locations (24)

Unknown

Inner Mongolia Baogang Hospital, Baotou

Beijing Chao-yang Hospital, Capital Medical University, Beijing

Peking Union Medical College Hospital, Beijing

The First Hospital of Jilin University, Changchun

The First People's Hospital of Changzhou, Changzhou

Foshan Nanhai People's Hospital, Foshan

Guangzhou First People's Hospital, Guangzhou

Nanfang Hospital, Guangzhou

The Second People's Hospital of Guangdong Province, Guangzhou

Zhujiang Hospital of Southern Medical University, Guangzhou

The First Affiliated Hospital Of University Of South China, Hengyang

Huzhou Third People's Hospital, Huzhou

First Affiliated Hospital of Kunming Medical University, Kunming

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

Affiliated Hospital of North Sichuan Medical College, Nanchong

Gulou Hospital Affiliated to Nanjing University Gulou Hospital Affiliated to Nanjing University, Nanjing

Zhongda Hospital Southeast University, Nanjing

Affiliated Hospital of Nantong University, Nantong

Ningbo Huamei Hospital, University of Chinese Academy of Sciences, Ningbo

Changhai Hospital of Shanghai, Shanghai

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

Qinghai Province People's Hospital, Xining

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Zigong Fourth People's Hospital, Zigong

Sponsors
All Listed Sponsors
lead

InventisBio Co., Ltd

INDUSTRY